within Pharmacolibrary.Drugs.ATC.A;

model A16AX10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.44,
    Cl             = 83.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 84 / 1000000,
    adminCount     = 1,
    Vd             = 0.796,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.009216666666666668,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Eliglustat is an oral substrate reduction therapy used for the long-term treatment of adults with Gaucher disease type 1, a lysosomal storage disorder. It inhibits glucosylceramide synthase, reducing the production of glycosphingolipids which accumulate in the disease. Eliglustat is approved and in current use for this indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters as observed in healthy adult volunteers after oral administration; population includes both sexes, ages 18-55 years.</p><h4>References</h4><ol><li><p>Thibault, N, et al., &amp; Turpault, S (2020). Effect of eliglustat on the pharmacokinetics of digoxin, metoprolol, and oral contraceptives and absorption of eliglustat when coadministered with acid-reducing agents. <i>Molecular genetics and metabolism</i> 129(4) 278–285. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2020.01.001&quot;>10.1016/j.ymgme.2020.01.001</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32029355/&quot;>https://pubmed.ncbi.nlm.nih.gov/32029355</a></p></li><li><p>Wang, Q, et al., &amp; Zhang, Q (2019). Drug-Drug Interactions Of Amiodarone And Quinidine On The Pharmacokinetics Of Eliglustat In Rats. <i>Drug design, development and therapy</i> 13 4207–4213. DOI:<a href=&quot;https://doi.org/10.2147/DDDT.S226948&quot;>10.2147/DDDT.S226948</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31849452/&quot;>https://pubmed.ncbi.nlm.nih.gov/31849452</a></p></li><li><p>Li, J, et al., &amp; Rudin, D (2020). Impact of hepatic and renal impairment on the pharmacokinetics and tolerability of eliglustat therapy for Gaucher disease type 1. <i>Molecular genetics and metabolism</i> 129(2) 117–124. DOI:<a href=&quot;https://doi.org/10.1016/j.ymgme.2019.11.002&quot;>10.1016/j.ymgme.2019.11.002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31924461/&quot;>https://pubmed.ncbi.nlm.nih.gov/31924461</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX10;
